Hepatitis C virus NS5A inhibitors and drug resistance mutations

World Journal of Gastroenterology

Volumn 20, Issue 11, 2014, Pages 2902-2912

  Nakamoto, Shingo ^a   Kanda, Tatsuo ^a   Wu, Shuang ^a   Shirasawa, Hiroshi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

ACH 3102; Daclatasvir; Direct acting antiviral agents; Hepatitis C virus; Ledipasvir

Indexed keywords

ACH 3102; ANTIVIRUS AGENT; DACLATASVIR; GSK 2336805; LEDIPASVIR; MK 874; NONSTRUCTURAL PROTEIN 5A; SAMATASVIR; UNCLASSIFIED DRUG; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DNA POLYMORPHISM; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 2A; HUMAN; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REPLICON; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; GENETICS; HEPACIVIRUS; MUTATION; VIROLOGY;

ANIMALS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; MUTATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896460675     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i11.2902     Document Type: Article

References (91)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237 [PMID: 10728807]
2. Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol 2010; 52: 72-78 [PMID: 19910070 DOI: 10.1016/j.jhep.2009.10.001]
3. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6547-6549 [PMID: 2168552]
4. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S-38S [PMID: 9305661]
5. Pacholczyk M, Giewska B, Lisik W, Tronina O, Wasiak D, Cieciura T, Chmura A. Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience. Ann Transplant 2012; 17: 5-10 [PMID: 23274318 DOI: 10.12659/AOT.883688]
6. Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, FukaiK, KanaiF, ImazekiF, YokosukaO. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 2009; 44: 872-877 [PMID: 19424931 DOI: 10.1080/00365520902937362]
7. Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Sugiura N, Tawada A, Wu S, Tanaka T, Nakamoto S, Mikata R, Tada M, Chiba T, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O. Quantification of hepatitisC virusin patientstreated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat 2011; 18: e292-e297 [PMID: 21129130 DOI: 10.1111/j.1365-2893.2010.01409.x]
8. Kanda T, Imazeki F, Azemoto R, Yonemitsu Y, Mikami S, Kita K, Takashi M, Sunaga M, Wu S, Nakamoto S, Tawada A, Arai M, Kato K, Yoshida Y, Koma Y, Fujiwara K, Fukai K, Suzuki N, Yokosuka O. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011; 56: 3335-3342 [PMID: 21604145 DOI: 10.1007/s10620-011-1750-7]
9. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-561 [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3]
10. Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007; 17: 245-252 [PMID: 17299803]
11. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 1995; 69: 3980-3986 [PMID: 7769656]
12. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502 [PMID: 15302943]
13. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227 [PMID: 9143277]
14. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218 [PMID: 9710605]
15. Polyak SJ, Paschal DM, McArdle S, Gale MJ, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999; 29: 1262-1271 [PMID: 10094974]
16. Gale M, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999; 73: 6506-6516 [PMID: 10400746]
17. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res 2000; 67: 173-178 [PMID: 10867196]
18. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75: 1401-1407 [PMID: 11152513]
19. Pflugheber J, Fredericksen B, Sumpter R, Wang C, Ware F, Sodora DL, Gale M. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci USA 2002; 99: 4650-4655 [PMID: 11904369]
20. Kanda T, Steele R, Ray R, Ray RB. Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice. J Virol 2009; 83: 8463-8469 [PMID: 19553305 DOI: 10.1128/JVI.00751-09]
21. Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T, Arai M, Fujiwara K, Saito K, Roger T, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C Virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011; 204: 793-801 [PMID: 21844306 DOI: 10.1093/infdis/jir381]
22. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 2004; 279: 48576-48587 [PMID: 15339921]
23. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005; 435: 374-379 [PMID: 15902263]
24. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 2009; 83: 4395-4403 [PMID: 19244328 DOI: 10.1128/JVI.02352-08]
25. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482-496 [PMID: 23748342 DOI: 10.1038/nrmicro3046]
26. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230 [PMID: 7542279]
27. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81 [PMID: 8531962]
28. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 750-753 [PMID: 9049230]
29. Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, Blum HE, Bartenschlager R, Moradpour D. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004; 279: 40835-40843 [PMID: 15247283]
30. Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, Shimada H, Tomonaga T, Nomura F, Nagao K, Ochiai T, Saisho H. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 2004; 11: 479-487 [PMID: 15500548]
31. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47 [PMID: 18537193 DOI: 10.1002/hep.22339]
32. Verdegem D, Badillo A, Wieruszeski JM, Landrieu I, Leroy A, Bartenschlager R, Penin F, Lippens G, Hanoulle X. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A. J Biol Chem 2011; 286: 20441-20454 [PMID: 21489988 DOI: 10.1074/jbc.M110.182436]
33. El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, Hotta H. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One 2012; 7: e30513 [PMID: 22319571 DOI: 10.1371/journal.pone.0030513]
34. El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012; 50: 3886-3892 [PMID: 22993188 DOI: 10.1128/JCM.02109-12]
35. Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog 2012; 8: e1002696 [PMID: 22654662 DOI: 10.1371/journal.ppat.1002696]
36. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Chemical geneticsstrategy identifiesan HCV NS5A inhibitorwith apotent clinical effect. Nature 2010; 465: 96-100 [PMID: 20410884 DOI: 10.1038/nature08960]
37. Lemm JA, Leet JE, O'Boyle DR, Romine JL, Huang XS, Schroeder DR, Alberts J, Cantone JL, Sun JH, Nower PT, Martin SW, Serrano-Wu MH, Meanwell NA, Snyder LB, Gao M. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemother 2011; 55: 3795-3802 [PMID: 21576451 DOI: 10.1128/AAC.00146-11]
38. Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar M, Klumpp K, Glenn JS. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 2011; 414: 10-18 [PMID: 21513964 DOI: 10.1016/j.virol.2011.03.026]
39. Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 2013; 110: 3991-3996 [PMID: 23431163 DOI: 10.1073/pnas.1203110110]
40. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-3650 [PMID: 20585111 DOI: 10.1128/AAC.00556-10]
41. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956-1965 [PMID: 21837752 DOI: 10.1002/hep.24609]
42. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2atrial. Lancet Infect Dis 2012; 12: 671-677 [PMID: 22714001 DOI: 10.1016/S1473-3099(12)70138-X]
43. Suk-Fong Lok A. HCV NS5A inhibitors in development. Clin Liver Dis 2013; 17: 111-121 [PMID: 23177287 DOI: 10.1016/j.cld.2012.09.006]
44. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59: 375-382 [PMID: 23567084 DOI: 10.1016/j.jhep.2013.03.030]
45. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013; 207 Suppl 1: S33-S39 [PMID: 23390303 DOI: 10.1093/infdis/jis761]
46. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503 [PMID: 23199507 DOI: 10.1016/j.bpg.2012.09.011]
47. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011; 1: 607-616 [PMID: 22440918 DOI: 10.1016/j.coviro.2011.10.019]
48. Londoño MC, Lens S, Forns X. Interferon free regimens forthe "difficult-to-treat": are we there? J Hepatol 2013; 58: 643-645 [PMID: 23333449 DOI: 10.1016/j.jhep.2013.01.007]
49. Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22: 1337-1346 [PMID: 23931586 DOI: 10.1517/13543784.2013.826189]
50. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 2011; 140: 1032-1042 [PMID: 21111742 DOI: 10.1053/j.gastro.2010.11.036]
51. Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J. Highly efficient infectiouscell culture of three hepatitisC virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology 2014; 59: 395-407 [PMID: 23913364 DOI: 10.1002/hep.26660]
52. Abe H, Hayes CN, Hiraga N, Imamura M, Tsuge M, Miki D, Takahashi S, Ochi H, Chayama K. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Am J Gastroenterol 2013; 108: 1464-1472 [PMID: 23896953 DOI: 10.1038/ajg.2013.205]
53. Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 2013; 62: 1055-1061 [PMID: 23322441 DOI: 10.1136/gutjnl-2012-302600]
54. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012; 56: 5230-5239 [PMID: 22850513 DOI: 10.1128/AAC.01209-12]
55. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 2011; 85: 7312-7320 [PMID: 21593143 DOI: 10.1128/JVI.00253-11]
56. Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Trépo C, Penin F, Deléage G. euHCVdb: the European hepatitis C virus database. Nucleic Acids Res 2007; 35: D363-D366 [PMID: 17142229]
57. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2013; 57: 611-613 [PMID: 23089758 DOI: 10.1128/AAC.01874-12]
58. Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O'Boyle DR, Gao M, Fridell RA. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 2012; 56: 1588-1590 [PMID: 22203595 DOI: 10.1128/AAC.06169-11]
59. Lawitz E, Marbury T, Cambell A, Dumas E, Kapoor M, Pilot-Matias T, Krishnan P, Setze C, Xie W, Podsadecki T, Bernstein B, Williams L. Safety and antiviral acyivity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT-1)-infected treatment-naive subject. J Hepatol 2012; 56 suppl 2: S469-S470 [47th annual meeting EASL abstract]
60. Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother 2013; 57: 5037-5044 [PMID: 23896477 DOI: 10.1128/AAC.00910-13]
61. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57: 24-31 [PMID: 22314425 DOI: 10.1016/j.jhep.2011.12.029]
62. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013; 3: 514-520 [PMID: 23896281 DOI: 10.1016/j.coviro.2013.06.014]
63. Cheng G, Yu M, Peng B, Lee YJ, Trejo-Martin A, Gong R, Bush C, Worth A, Nash M, Chan K, Yang H, Beran R, Tian Y, Perry J, Taylor J, Yang C, Paulson M, Delaney W, Link JO. GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J Hepatol 2013; 58 suppl 1: S484-S485 [48th annual meeting EASL abstract]
64. Yang G, Wiles J, Patel D, Zhao Y, Fabrycki J, Weinheimer S, Marlor C, Rivera J, Wang Q, Gadhachanda V, Hashimoto A, Chen D, Pais G, Wang X, Deshpande M, Stauber K, Huang M, Phadke A. Preclinical characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype-1a virus and variants resistant to 1st generation of NS5A inhibitors. J Hepatol 2012; 56 suppl 2: S330 [DOI: 10.1016/S0168-8278(12)60857-5]
65. Liu R, Kong R, Mann P, Ingravallo P, Zhai Y, Xia E, Ludmerer S, Kozlowski J, Coburn C. In vitro resistance analysis of HCV NS5A inhibitor: MK-8742 demonstrates increased potency against clinical resistance variants and higher resisitance barrier. J Hepatol 2012; 56 suppl 2: S334-S335 [DOI: 10.1016/S0168-8278(12)60870-8]
66. Fridell RA, Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-1935 [PMID: 21809362 DOI: 10.1002/hep.24594]
67. Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Roberts S, Fridell RA, Gao M. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013; 57: 2054-2065 [PMID: 23403428 DOI: 10.1128/AAC.02494-12]
68. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544-1553 [PMID: 23152524 DOI: 10.1128/JVI.02294-12]
69. Kuiken C, Hraber P, Thurmond J, Yusim K. The hepatitis C sequence database in Los Alamos. Nucleic Acids Res 2008; 36: D512-D516 [PMID: 18025038]
70. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 2013; 57: 13-18 [PMID: 23384816 DOI: 10.1016/j.jcv.2012.12.020]
71. Plaza Z, Soriano V, Vispo E, del Mar Gonzalez M, Barreiro P, Seclén E, Poveda E. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17: 921-926 [PMID: 22436385 DOI: 10.3851/IMP2091]
72. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54: 352-354 [PMID: 22658798 DOI: 10.1016/j.jcv.2012.04.024]
73. Lalezari JP, Farrell GC, Shah PS, Schwab C, Walsh D, Vig P, Brown NA, Ruby E, Halfon S, Colonno R, Li L, Johnston B, Wargin W, Gane EJ. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety. Hepatology 2012; 56 Suppl: 1065A
74. McCarville JF, Seifer M, Standring DN, Mayers DL. IDX-06A-001 Investigator Team. Treatment-emergent variants following 3 days of monotherapy with IDX719, a potent, pan-genotypic NS5A inhibitor, in subjects infected with HCV genotypes 1-4. J Hepatol 2013; 58 suppl 1: S491-S492 [48th annual meeting EASL abstract]
75. Yang G, Patel D, Zhao Y, Fabrycki J, Yang W, Podos S, Robison H, Robarge L, Kocinsky H, Deshpande M, Huang M. Findings from clinical virology studies on ACH-3102 are consistent with preclinical observations on its improved potency against genotype-1a HCV and resistant variants. J Hepatol 2013; 58 suppl 1: S487-S488 [DOI: 10.1016/S0168-8278(13)61200-3]
76. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 2013; 57: 6333-6340 [PMID: 23877691]
77. Sun JH, O'Boyle Ii DR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012; 55: 1692-1699 [PMID: 22234905 DOI: 10.1002/hep.25581]
78. Hezode C, Hirschfield GM, Ghesquiere W, Sievert Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat GE, Lawitz E, Rustgi VK, Pol S, Weis n, Pockros P, Bourliere M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Liu Z, Hughes EA, Schnittman SM, Yin PD. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive hcv-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results. Hepatology 2012; 56 suppl: 553A
79. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-662 [PMID: 23183526 DOI: 10.1016/j.jhep.2012.09.037]
80. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-654 [PMID: 23178977 DOI: 10.1016/j.jhep.2012.11.012]
81. Lok AS, Gardiner DF, Hezode C, Lawitz E, Bourliere M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Wind-Rotolo M, McPhee F, Grasela DM, Pasquinelli C. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Hepatology 2012; 56 suppl: 230A
82. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224 [PMID: 22256805 DOI: 10.1056/NEJMoa1104430]
83. Hernandez D, Yu F, Ueland J, Wang C, Huang H, Gardiner D, Fridell R, Gao M. Characterization of virologic escape in hcv genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. J Hepatol 2011; 54 suppl 1: S28-S29 [DOI: 10.1016/S0168-8278(11)60065-2]
84. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58: 428-438 [PMID: 23467911 DOI: 10.1002/hep.26371]
85. Aghemo A, Colombo M. Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. Gastroenterology 2013; 145: 247-249 [PMID: 23726875 DOI: 10.1053/j.gastro.2013.05.028]
86. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58: 583-592 [PMID: 23104162 DOI: 10.1016/j.jhep.2012.10.019]
87. Kowdley K, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo PY, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen LM, Khatri A, Podsadecki TJ, Bernstein B. A 12-week Interferon-free Treatment Regimen With ABT-450/r, ABT 267, ABT-333, and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-naive Patients and 93% in Prior Null Responders With HCV Genotype 1 Infection. Hepatology 2012; 56: 1515A-1516A
88. Everson GT, Sims KD, Rodriguez-Torres, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi VK, Schwartz H, Tatum HA, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naive Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection. Hepatology 2012; 56: 1517A-1518A
89. Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson IM, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang SP, Gao M, McPhee F, Sherman D, Hindes R, Symonds WT, Pasquinelli C, Grasela DM. High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3. Hepatology 2012; 56: 1516A-1517A
90. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson IM, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang SP, Gao M, McPhee F, Sherman D, Hindes R, Symonds WT, Pasquinelli C, Grasela DM, AI444040 Study Group. Sustained Virologic Response With Daclatasvir Plus Sofosbuvir Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC). J Hepatol 2013; 58: S570
91. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, Hamid S, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, McCaughan WG. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435 [DOI: 10.1007/s12072-012-9342-y]